A Randomized, Double-Blind, Parallel, Three Arm, Multicenter, Phase II Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Taxol�/Paraplatin� (Paclitaxel/Carboplatin) Compared to Taxol�/Paraplatin� Alone in Previously U

To compare the immune-related progression free survival (irPFS) of subjects receiving ipilimumab in combination with concurrent Taxol�/Paraplatin� (�concurrent�; Arm A) to that of subjects receiving Taxol�/Paraplatin� alone (Arm C) in Stage IIIb/IV NSCLC subjects using irRC as per the assessment of an independent review committee (IRC).